DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184430

Plasma homocysteine levels in Indian patients with acute ischemic stroke

Deepa Alloli, G. S. Mahishale, Siddaraya Hanjagi, Sayed Mohammed Meraj Hussaini, Ganga Patil

Abstract


Background: Homocysteine has primary atherogenic and prothrombotic properties. The present study aimed to assess serum homocysteine levels in patients with ischemic stroke and to find association of serum homocysteine levels with various patient related variables.

Methods: This observational study included patients who were admitted with the diagnosis of stroke in Sri Ventateswara Ramnarain Ruia Government General Hospital. Patients were evaluated for risk factors like hypertension, diabetes mellitus and hyperlipidemia. Total homocysteine estimation was done and survival of the patients was assessed at the time of discharge from the hospital.

Results: Most common risk factor for stroke in our study population was dyslipidemia (40%), followed by hypertension (36%). Total homocysteine levels were raised in 92% of the patients. Patients with homocysteine levels less than 15mM/L had lacunar infarcts. Homocysteine levels higher than 100mM/L were found in 18% of the patients and they all had large sized lesions. Significantly higher mean homocysteine levels were found among patients with large lesions (70.15±2.65 vs 21.68±8.02, p value <0.05). Among various risk factors, higher mean homocysteine levels were found to be associated with dyslipidemia (p value <0.05). No association between hypertension, diabetes mellitus or smoking history was found with higher homocysteine levels. Patients who survived had significantly lower homocysteine levels as compared to non survivors (39.3±19.84 vs 100±18.82, p value<0.001).

Conclusions: Further studies are needed on homocysteine and stroke fur using homocysteine as screening test and for initiation of preventive therapy of stroke based on homocysteine levels.


Keywords


Homocysteine, Ischemic stroke, Stroke

Full Text:

PDF

References


McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386.

Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, et al. Hyperhomocysteinemia-induced vascular damage in the minipig: captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation. 1995 Feb 15;91(4):1161-74.

Torbus-Lisiecka B, Bukowska H, Jastrzebska M, Chelstowski K, Honczarenko K, Naruszewicz M. Homocysteine and a family history of early ischemic cerebral stroke. Nutr Meta Cardiovasc Dis. 2001;11(Suppl 5):52-9.

Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation. 1997;95:1119-21.

Bhargava S, Parakh R, Srivastava LM. Studies on homocysteine demonstrating its significance as a possible tool for differential diagnosis in occlusive vascular Disease. Ind J Clin Biochem. 2004;19(1):76-8.

Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006;136(6Suppl):1741S-1749S.

Nagai Y, Takamura T, Nohara E. Acute hyperinsulinemia reduces plasma concentrations of homocysteine in healthy men. Diabetes Care. 1999;22(6):1004.

McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-27.

Shi Z, Liu S, Guan Y, Zhang M, Lu H, Yue W, et al. Changes in total homocysteine levels after acute stroke and recurrence of stroke. Scientific reports. 2018 May 3;8(1):6993.

Ma Y, Li L, Geng XB, Hong Y, Shang XM, Tan Z, et al. Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction. Am J Therapeutics. 2016;23(6):e1464-8.

Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274(13):1049-57.

Gungor L, Polat M, Ozberk MB, Avci B, Abur U. Which Ischemic Stroke Subtype Is Associated with Hyperhomocysteinemia?. J Stroke Cerebrovas Dis. 2018 Jul 1;27(7):1921-9.

Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst (e) ine and cardiovascular disease: a critical review of the epidemiologic evidence. Annals of internal medicine. 1999 Sep 7;131(5):363-75.

Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual?. Archives Inter Med. 2000 Feb 28;160(4):422-34.